| 51 |
19196886 | Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome. | 2009 May |
1 |
| 52 |
19332965 | Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? | 2009 Mar |
2 |
| 53 |
19409352 | Recent advances in cardiovascular risk reduction: implications of ONTARGET. | 2009 |
1 |
| 54 |
19433778 | Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. | 2009 Jul |
2 |
| 55 |
19436659 | Results of the ONTARGET and TRANSCEND studies: an update and discussion. | 2009 |
2 |
| 56 |
19925416 | Angiotensin converting enzyme (ACE) inhibitory peptides: production and implementation of functional food. | 2009 |
1 |
| 57 |
20066882 | [Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients]. | 2009 Nov |
1 |
| 58 |
20165647 | Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope? | 2009 Jul |
1 |
| 59 |
17984104 | Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. | 2008 Feb |
1 |
| 60 |
18098237 | Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. | 2008 Mar |
1 |
| 61 |
18312901 | Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. | 2008 Feb |
1 |
| 62 |
18398348 | Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. | 2008 May |
1 |
| 63 |
18427133 | Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. | 2008 Apr 29 |
1 |
| 64 |
18458262 | Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. | 2008 May 6 |
1 |
| 65 |
18516782 | [Choroidal effusion after uncomplicated cataract surgery]. | 2008 Jun |
1 |
| 66 |
18551027 | The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. | 2008 Jul |
2 |
| 67 |
18625157 | Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients? | 2008 Aug |
2 |
| 68 |
18652658 | First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. | 2008 Jul 24 |
1 |
| 69 |
18847425 | [Advances in diabetes mellitus, diabetic nephropathy, metabolic syndrome and cardio-vascular-renal risk]. | 2008 |
1 |
| 70 |
19240304 | Ramipril: the better angiotensin-converting enzyme inhibitor? | 2008 May-Jun |
1 |
| 71 |
19555040 | [Hartil effects on structural-functional condition of the heart in patients with chronic cor pulmonale]. | 2008 |
1 |
| 72 |
20409933 | 24-hour powerful blood pressure-lowering: is there a clinical need? | 2008 Jul-Aug |
1 |
| 73 |
17143175 | A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. | 2007 Jan |
2 |
| 74 |
17560452 | Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. | 2007 Jul |
1 |
| 75 |
17679038 | Differential effects of ramipril on ambulatory blood pressure in African Americans and Caucasians. | 2007 Aug |
1 |
| 76 |
17719288 | Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. | 2007 Sep |
1 |
| 77 |
17885551 | Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. | 2007 Oct |
2 |
| 78 |
17978596 | Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients. | 2007 Nov |
1 |
| 79 |
18158708 | Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler. | 2007 Dec |
1 |
| 80 |
16398929 | Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat. | 2006 Jan 6 |
1 |
| 81 |
16732017 | Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study. | 2006 Jun |
1 |
| 82 |
16896999 | Different pathomechanisms of essential and obesity-associated hypertension in adolescents. | 2006 Oct |
1 |
| 83 |
17019594 | Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects. | 2006 Dec |
2 |
| 84 |
17192135 | Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. | 2006 |
1 |
| 85 |
15677497 | Hyperglycemia activates JAK2 signaling pathway in human failing myocytes via angiotensin II-mediated oxidative stress. | 2005 Feb |
1 |
| 86 |
15715683 | Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. | 2005 Mar |
1 |
| 87 |
15766995 | Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. | 2005 Mar 12-18 |
1 |
| 88 |
15868362 | Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. | 2005 May |
3 |
| 89 |
15938036 | Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. | 2005 Mar |
2 |
| 90 |
16003858 | Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events. | 2005 Jun |
2 |
| 91 |
16112972 | The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. | 2005 |
1 |
| 92 |
16157080 | The African American Study of Kidney Disease: do these results indicate that 140/90 mm hg is good enough? | 2005 Oct |
1 |
| 93 |
16205450 | Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study. | 2005 Nov |
3 |
| 94 |
16222899 | Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. | 2005 |
2 |
| 95 |
16269994 | Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors. | 2005 Oct 22 |
2 |
| 96 |
16285075 | Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. | 2005 Oct |
2 |
| 97 |
16382264 | Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors? | 2005 Dec |
2 |
| 98 |
16405197 | Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors? | 2005 Dec |
2 |
| 99 |
12754187 | Angiotensin II and the fibroproliferative response to acute lung injury. | 2004 Jan |
2 |
| 100 |
14871059 | What have we learned from the current trials? | 2004 Jan |
1 |